title: Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo.
abstract: The purpose of the present study was to evaluate zuclopenthixol acetate in Viscoleo, a new preparation to be administered once every 3 days, in the early treatment of acute psychotic episodes and acute deterioration of chronic psychosis. 21 cases were included in the study: patients received 1 to 3 injections. Clinical evaluation was made at 24, 48 and 72 hours after each injection, using the Clinical Global Impressions (CGI) and the Brief Psychiatric Rating Scale (BPRS). Results at end-point indicated a marked or moderate therapeutic effect in the 11 cases of acute psychosis. A statistically significant decrease was observed for the total BPRS score as well as for its subscales. Among 8 cases of exacerbation of chronic psychosis, 4 patients showed a moderate therapeutic effect, and minimal or no effect was found in the other 4 subjects. The total BPRS decreased significantly, but to a lesser extent than for acute psychosis. Two patients suffering from mania showed a moderate therapeutic effect according to CGI. 8 cases of acute psychosis and 5 cases of chronic psychosis did not suffer from any neurological side-effects. Plasma concentration measurements suggest that a dose of 50 mg per 3 days may be sufficient for early treatment of most acutely ill psychotic patients.
authors.affiliation: Department of Psychiatry, University of Geneva, Switzerland.
authors.forename: L P
authors.initials: LP
authors.lastname: Balant
authors.forename: A E
authors.initials: AE
authors.lastname: Balant-Gorgia
authors.forename: R
authors.initials: R
authors.lastname: Eisele
authors.forename: B
authors.initials: B
authors.lastname: Reith
authors.forename: M
authors.initials: M
authors.lastname: Gex-Fabry
authors.forename: G
authors.initials: G
authors.lastname: Garrone
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D003006:Clopenthixol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D013892:Thioxanthenes / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D013892:Thioxanthenes; C060342:clopenthixol acetate ester; D003006:Clopenthixol